company background image
600329 logo

Tianjin Pharmaceutical Da Ren Tang Group XSSC:600329 Stock Report

Last Price

CN¥27.88

Market Cap

CN¥18.8b

7D

-3.5%

1Y

-28.5%

Updated

27 Mar, 2024

Data

Company Financials +

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

XSSC:600329 Stock Report

Market Cap: CN¥18.8b

600329 Stock Overview

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China.

600329 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends4/6

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tianjin Pharmaceutical Da Ren Tang Group
Historical stock prices
Current Share PriceCN¥27.88
52 Week HighCN¥56.26
52 Week LowCN¥23.40
Beta0.71
1 Month Change-4.75%
3 Month Change-16.07%
1 Year Change-28.49%
3 Year Change30.95%
5 Year Change68.36%
Change since IPO81.27%

Recent News & Updates

Recent updates

Shareholder Returns

600329CN PharmaceuticalsCN Market
7D-3.5%-3.4%-2.2%
1Y-28.5%-11.4%-14.8%

Return vs Industry: 600329 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.

Return vs Market: 600329 underperformed the CN Market which returned -14.8% over the past year.

Price Volatility

Is 600329's price volatile compared to industry and market?
600329 volatility
600329 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.4%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 600329's share price has been volatile over the past 3 months.

Volatility Over Time: 600329's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19814,913Lei Wanghttps://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary

How do Tianjin Pharmaceutical Da Ren Tang Group's earnings and revenue compare to its market cap?
600329 fundamental statistics
Market capCN¥18.77b
Earnings (TTM)CN¥991.03m
Revenue (TTM)CN¥8.48b

21.7x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600329 income statement (TTM)
RevenueCN¥8.48b
Cost of RevenueCN¥4.90b
Gross ProfitCN¥3.58b
Other ExpensesCN¥2.58b
EarningsCN¥991.03m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 30, 2024

Earnings per share (EPS)1.29
Gross Margin42.17%
Net Profit Margin11.69%
Debt/Equity Ratio11.9%

How did 600329 perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

87%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.